Framycetin

Details

• Internal ID: 5adb094e-d66b-407b-bf30-1286efb5473d
• Taxonomy: Organic oxygen compounds > Organooxygen compounds > Carbohydrates and carbohydrate conjugates > 2-deoxystreptamine aminoglycosides > 4,5-disubstituted 2-deoxystreptamines
• IUPAC Name: (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
• SMILES (Canonical): C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N
• SMILES (Isomeric): C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N
• InChI: InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
• InChI Key: PGBHMTALBVVCIT-VCIWKGPPSA-N
• Popularity: 1,420 references in papers

Physical and Chemical Properties

• Molecular Formula: C₂₃H₄₆N₆O₁₃
• Molecular Weight: 614.60 g/mol
• Exact Mass: 614.31228554 g/mol
• Topological Polar Surface Area (TPSA): 353.00 Ų
• XlogP: -9.00
• Atomic LogP (AlogP): -8.90
• H-Bond Acceptor: 19
• H-Bond Donor: 13
• Rotatable Bonds: 9

Synonyms

• neomycin
• NEOMYCIN B
• 119-04-0
• Fradiomycin
• Mycifradin
• Soframycin
• Fradiomycin B
• Enterfram
• Framygen
• Actilin
• Neomas
• Fradiomycinum
• Framicetina
• Framycetine
• Framycetinum
• Caswell No. 595
• Nivemycin
• Neomycin B sulfate
• Antibiotic 10676
• NEOMYCIN SULFATE
• 1404-04-2
• Neobrettin
• USAF CB-19
• CCRIS 5462
• Framidal
• Framycin
• Francetin
• Dekamycin iii
• HSDB 3242
• Soframycine
• Actiline
• Framycetin (INN)
• Neo-Rx
• Antibiotique
• Myacyne
• Neolate
• (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
• ANTIBIOTIQUE EF 185
• Neomycin sulphate
• CHEBI:7508
• Vonamycin powder V
• Neomcin
• Neomin
• 4BOC774388
• (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside
• Neomicina [DCIT]
• Framycetinum [INN-Latin]
• Neomicina
• Neomycine
• Neomycinum
• PIMAVECORT
• FRAMYCETIN [INN]
• Neomycine [INN-French]
• Neomycinum [INN-Latin]
• Framycetine [INN-French]
• NMY
• Framicetina [INN-Spanish]
• Framycetin [INN:BAN:DCF]
• Bycomycin
• Jernadex
• Fradiomycin B;Neomycin B
• Neomycin [INN:BAN]
• EINECS 204-292-2
• EINECS 215-766-3
• EPA Pesticide Chemical Code 006303
• BRN 0101621
• Mycerin
• UNII-I16QD7X297
• UNII-4BOC774388
• Antibiotic 956
• (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxy-tetrahydropyran-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]oxy-3-hydroxy-cyclohexoxy]tetrahydropyran-3,4-diol
• NEOMYCINB
• Antibiotic produced by Streptomyces decaris. Neomycin B
• NEOMYCIN B [MI]
• Prestwick3_000158
• Neomycin B; Fradiomycin B
• SCHEMBL3279
• FRAMYCETIN [WHO-DD]
• BSPBio_000296
• GTPL709
• NEOMYCIN B [USP-RS]
• 4-18-00-07476 (Beilstein Handbook Reference)
• D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-
• BPBio1_000326
• CHEMBL184618
• DTXSID2023359
• HMS2089P15
• I16QD7X297
• AKOS024284361
• CS-6390
• DB00452
• NCGC00179612-01
• D-Streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1.->3)-O-.beta.-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy
• HY-17624
• AB00443887
• C01737
• D05140
• AB00443887-03
• EN300-7480789
• MYCIFRADIN; NEOMAS; PIMAVECORT; VONAMYCIN
• ANTIBIOTIC PRODUCED BY STREPTOMYCES DECARIS
• J-004060
• Q4492348
• BRD-K71013094-065-01-2
• (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2-{[(2S,3R,4S,5R)-4-{[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}oxane-3,4-diol
• 11004-65-2
• 6-(2-{(4S,2R,3R,5R)-4-[(5S,6S,2R,3R,4R)-3-amino-6-(aminomethyl)-4,5-dihydroxy( 2H-3,4,5,6-tetrahydropyran-2-yloxy)]-3-hydroxy-5-(hydroxymethyl)oxolan-2-yloxy }(3S,6S,1R,2R,4R)-4,6-diamino-3-hydroxycyclohexyloxy)(3S,2R,4R,5R,6R)-5-amino- 2-(aminomethyl)-2H
• D-STREPTAMINE, O-2,6-DIAMINO-2,6-DIDEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(O-2,6-DIAMINO-2,6-DIDEOXY-.BETA.-L-IDOPYRANOSYL-(1->3)-.BETA.-D-RIBOFURANOSYL-(1->5))-2-DEOXY-
• D-STREPTAMINE, O-2,6-DIAMINO-2,6-DIDEOXY-.BETA.-L-IDOPYRANOSYL-(1->3)-O-.BETA.-D-RIBOFURANOSYL-(1->5)-O-(2,6-DIAMINO-2,6-DIDEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4))-2-DEOXY-

2D Structure

ADMET Properties (via admetSAR 2)

Target	Value	Probability (raw)	Probability (%)
Human Intestinal Absorption	-	0.9690	96.90%
Caco-2	-	0.8825	88.25%
Blood Brain Barrier	-	0.9250	92.50%
Human oral bioavailability	-	0.9857	98.57%
Subcellular localzation	Lysosomes	0.5216	52.16%
OATP2B1 inhibitior	-	0.8631	86.31%
OATP1B1 inhibitior	+	0.9481	94.81%
OATP1B3 inhibitior	+	0.9492	94.92%
MATE1 inhibitior	-	0.9800	98.00%
OCT2 inhibitior	-	0.8250	82.50%
BSEP inhibitior	-	0.9051	90.51%
P-glycoprotein inhibitior	-	0.8811	88.11%
P-glycoprotein substrate	-	0.8800	88.00%
CYP3A4 substrate	+	0.5310	53.10%
CYP2C9 substrate	-	1.0000	100.00%
CYP2D6 substrate	-	0.7688	76.88%
CYP3A4 inhibition	-	0.9471	94.71%
CYP2C9 inhibition	-	0.9147	91.47%
CYP2C19 inhibition	-	0.9034	90.34%
CYP2D6 inhibition	-	0.9231	92.31%
CYP1A2 inhibition	-	0.9157	91.57%
CYP2C8 inhibition	-	0.7398	73.98%
CYP inhibitory promiscuity	-	0.8446	84.46%
UGT catelyzed	+	0.8000	80.00%
Carcinogenicity (binary)	-	1.0000	100.00%
Carcinogenicity (trinary)	Non-required	0.6540	65.40%
Eye corrosion	-	0.9887	98.87%
Eye irritation	-	0.9135	91.35%
Skin irritation	-	0.7944	79.44%
Skin corrosion	-	0.9205	92.05%
Ames mutagenesis	-	0.6754	67.54%
Human Ether-a-go-go-Related Gene inhibition	+	0.7469	74.69%
Micronuclear	+	0.7800	78.00%
Hepatotoxicity	-	1.0000	100.00%
skin sensitisation	-	0.9435	94.35%
Respiratory toxicity	+	0.6444	64.44%
Reproductive toxicity	+	1.0000	100.00%
Mitochondrial toxicity	+	0.9250	92.50%
Nephrotoxicity	-	0.8449	84.49%
Acute Oral Toxicity (c)	IV	0.6098	60.98%
Estrogen receptor binding	+	0.5371	53.71%
Androgen receptor binding	-	0.8513	85.13%
Thyroid receptor binding	+	0.5236	52.36%
Glucocorticoid receptor binding	+	0.5462	54.62%
Aromatase binding	-	0.4912	49.12%
PPAR gamma	+	0.6280	62.80%
Honey bee toxicity	-	0.6547	65.47%
Biodegradation	-	0.7500	75.00%
Crustacea aquatic toxicity	-	0.7000	70.00%
Fish aquatic toxicity	-	0.9655	96.55%

Targets

Proven Targets:

CHEMBL ID	UniProt ID	Name	Min activity	Assay type	Source
CHEMBL4794	Q8NER1	Vanilloid receptor	400 nM	IC50	via Super-PRED

Predicted Targets (via Super-PRED):

CHEMBL ID	UniProt ID	Name	Probability	Model accuracy
CHEMBL3137262	O60341	LSD1/CoREST complex	97.46%	97.09%
CHEMBL5619	P27695	DNA-(apurinic or apyrimidinic site) lyase	97.00%	91.11%
CHEMBL226	P30542	Adenosine A1 receptor	95.26%	95.93%
CHEMBL6136	O60341	Lysine-specific histone demethylase 1	92.83%	95.58%
CHEMBL3251	P19838	Nuclear factor NF-kappa-B p105 subunit	92.64%	96.09%
CHEMBL2996	Q05655	Protein kinase C delta	91.14%	97.79%
CHEMBL4016	P42262	Glutamate receptor ionotropic, AMPA 2	83.94%	86.92%
CHEMBL5608	Q16288	NT-3 growth factor receptor	83.11%	95.89%
CHEMBL3589	P55263	Adenosine kinase	83.10%	98.05%
CHEMBL4203	Q9HAZ1	Dual specificity protein kinase CLK4	82.63%	94.45%
CHEMBL4187	Q99250	Sodium channel protein type II alpha subunit	81.26%	95.50%
CHEMBL3880	P07900	Heat shock protein HSP 90-alpha	80.43%	96.21%

Plants that contains it

• Glycine max

Cross-Links

• PubChem: 8378
• LOTUS: LTS0042651
• wikiData: Q105140378